North Dakota Code 50-24.6-05 – Public notice – Applicability
1. The department shall provide thirty days’ notice of all meetings of the board. The notice requirement is met if the department provides notice of the meeting on the department’s website and provides, by written or electronic means, individual notice to each person that has requested such notice. If the meeting agenda includes board consideration of a change to the prior authorization program, the department shall include in the notice a list of the affected drugs, and upon request the board shall provide background information. Any interested party may attend a meeting of the board and provide information or recommendations related to the inclusion of a drug in a prior authorization program.
Terms Used In North Dakota Code 50-24.6-05
- following: when used by way of reference to a chapter or other part of a statute means the next preceding or next following chapter or other part. See North Dakota Code 1-01-49
- Individual: means a human being. See North Dakota Code 1-01-49
- Person: means an individual, organization, government, political subdivision, or government agency or instrumentality. See North Dakota Code 1-01-49
- written: include "typewriting" and "typewritten" and "printing" and "printed" except in the case of signatures and when the words are used by way of contrast to typewriting and printing. See North Dakota Code 1-01-37
2. The department shall post on the department’s website:
a. The most current and applicable list of drugs requiring prior authorization, together with any limits on coverage of these drugs.
b. In downloadable format, forms necessary to complete prior authorization requests.
c. Decisions regarding changes to the prior authorization program list. The department shall allow a period of no less than thirty days for public comment following posting on the website.
d. Meeting notice.
3. The department may not discontinue the provision of prescription drug benefits being provided to medical assistance recipients before April 14, 2003, based solely on the subsequent placement of the drug on the prior authorization program.